Header Logo

Connection

CHARLES WYKOFF to Macular Degeneration

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Macular Degeneration.
CHARLES WYKOFF
Connection Strength
10.511
Macular Degeneration
  1. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025 Aug; 276:350-364.
    View in: PubMed
    Score: 0.828
  2. Distinguishing ABCA4 from PRPH2-related disease: qualitative analysis of examination and imaging features. Ophthalmic Genet. 2025 Aug; 46(4):347-353.
    View in: PubMed
    Score: 0.805
  3. Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol. 2024 Jan 01; 35(1):64-72.
    View in: PubMed
    Score: 0.744
  4. Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):589-598.
    View in: PubMed
    Score: 0.743
  5. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022 12; 7(1).
    View in: PubMed
    Score: 0.704
  6. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
    View in: PubMed
    Score: 0.644
  7. Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. BioDrugs. 2021 May; 35(3):303-323.
    View in: PubMed
    Score: 0.628
  8. Reply. Ophthalmol Retina. 2021 01; 5(1):e1-e2.
    View in: PubMed
    Score: 0.614
  9. Re: Adrean et?al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). Ophthalmology. 2019 03; 126(3):e18-e19.
    View in: PubMed
    Score: 0.541
  10. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
    View in: PubMed
    Score: 0.502
  11. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
    View in: PubMed
    Score: 0.485
  12. Quantitative comparison of inner and outer retinal intraretinal hyperreflective foci in age-related macular degeneration. Exp Eye Res. 2025 Jul; 256:110415.
    View in: PubMed
    Score: 0.207
  13. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
    View in: PubMed
    Score: 0.197
  14. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 10 21; 402(10411):1434-1448.
    View in: PubMed
    Score: 0.186
  15. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina. 2023 07 01; 43(7):1051-1063.
    View in: PubMed
    Score: 0.182
  16. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry. Ophthalmology. 2023 09; 130(9):937-946.
    View in: PubMed
    Score: 0.180
  17. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
    View in: PubMed
    Score: 0.179
  18. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
    View in: PubMed
    Score: 0.178
  19. Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2023 03; 247:137-144.
    View in: PubMed
    Score: 0.174
  20. OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration. Ophthalmol Retina. 2023 03; 7(3):253-260.
    View in: PubMed
    Score: 0.174
  21. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
    View in: PubMed
    Score: 0.169
  22. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2022 Jan 01; 140(1):20-28.
    View in: PubMed
    Score: 0.165
  23. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Ophthalmol Retina. 2022 05; 6(5):377-386.
    View in: PubMed
    Score: 0.164
  24. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. Ophthalmol Retina. 2022 03; 6(3):219-227.
    View in: PubMed
    Score: 0.160
  25. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 01; 139(5):542-547.
    View in: PubMed
    Score: 0.157
  26. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
    View in: PubMed
    Score: 0.148
  27. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
    View in: PubMed
    Score: 0.143
  28. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
    View in: PubMed
    Score: 0.139
  29. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad. Am J Ophthalmol. 2016 09; 169:xiv-xvi.
    View in: PubMed
    Score: 0.113
  30. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
    View in: PubMed
    Score: 0.112
  31. Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
    View in: PubMed
    Score: 0.049
  32. Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
    View in: PubMed
    Score: 0.048
  33. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.